“Biopharmaceutical Excipients Market Report is set to have rapid growth due Presence of diversified suppliers and strong research funding in chemicals division at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biopharmaceutical Excipients Market Forecast 2019-2029: By Product (Solubilizers & Surfactants/Emulsifiers, Specialty Excipients, Polyols, Carbohydrates), By Region, And Segment Forecasts.

The global Biopharmaceutical Excipients market is poised for rapid growth between 2019 and 2029. Factors such as the growing pharmaceutical industry combined with advances in functional excipients, the growing adoption of orphan drugs and the increasing uptake of biopharmaceuticals are driving the market for pharmaceutical excipients.

Some recent advancements include:

  • On December 2018, Roquette Feres (France) signed an agreement with Thermo Fisher Scientific (USA), which gives Thermo Fisher the right to distribute Roquette's product portfolio in the United States and Canada.
  • On January 2019, Croda International (United Kingdom) acquired Brenntag Biosector (Denmark) for its portfolio of vaccine adjuvants that would complement Croda's portfolio of pharmaceutical excipients.
  • On April 2019, Colorcon, Inc. (United States) signed an agreement with DuPont Nutrition and Biosciences (United States) to improve the current portfolio of CR Alliance products.
  • Onn February 2019, Associated British Foods plc (United Kingdom) signed an agreement with Indchem International (India) on the basis of which Indchem will distribute the functional lipid excipient product line of the Associated British Food on the Indian market.

Leading companies featured in the report include ABITEC Corp.; Signet Chemical Corporation Pvt. Ltd.; Roquette; Sigachi Industries Pvt. Ltd.; Meggle AG; Colorcon, Inc.; DFE Pharma; Clariant; IMCD; SPI Pharma; Pharmonix Biological Pvt. Ltd.; Spectrum Chemical Manufacturing Corp., and BASF SE

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever